IN8bio

Q2 FY2026 EarningsQ2 FY26 results beat consensus estimates across all bottom-line metrics, primarily driven by disciplined operating expense management. The reported net loss was -$4.78M compared to the -$5.61M analyst consensus, resulting in an EPS of -$0.25, significantly better than the -$0.37 expected. Despite the financial beat, management flagged a "substantial doubt" regarding the going concern, with $18.0M in cash only providing a runway through April 2027. Clinical focus remains on the INB-100 expansion and the INB-600 TCE platform, with initial in vivo data expected in H2 2026.